Orca Biosystems Inc.

Orca Biosystems Inc. is a U. S. -based biotechnology firm specializing in high-precision cell therapies, particularly investigational allogeneic T-cell immunotherapies for cancer and autoimmune diseases.

Founded in 2016 in Menlo Park, California, Orca Biosystems Inc. focuses on developing advanced cell therapies. The company was established by founders Ivan Dimov, Jeroen Bekaert, Nathaniel Fernhoff, and Ronald Martell. Their innovative approach has garnered attention, leading to a total of 6 deals, with the most recent funding round being Series F, raising USD 167.

967 mn led by Lightspeed Venture Partners. The company currently holds a valuation of USD 2,159. 450 mn. Orca Bio specializes in developing high-precision cell therapies, particularly investigational allogeneic T-cell immunotherapies aimed at treating cancer and autoimmune diseases.

These therapies leverage regulatory T cells to enhance patient outcomes while minimizing associated risks. The company seeks to address the critical need for effective cancer treatments and manage autoimmune disorders through its innovative product offerings. Orca Bio’s primary client base includes healthcare providers, hospitals, and research institutions primarily located in North America and Europe. Their solutions are designed to expand the therapeutic benefits of cell therapies, ultimately improving the quality of life for patients facing these challenging health issues.

Orca Bio's revenue model is centered around partnerships and collaborations with healthcare institutions, focusing on the commercialization of its advanced cell therapy products. The company engages directly with hospitals and treatment centers, facilitating the integration of its therapies into clinical practice. Transactions typically involve agreements for the provision of their flagship therapies, such as Orca-T and Orca-Q, which may be priced based on specific treatment protocols and patient needs. These offerings are utilized in specialized treatment settings, where healthcare providers implement Orca Bio's therapies as part of comprehensive patient care plans.

The revenue structure is built upon direct-to-provider relationships, enhancing accessibility to their innovative solutions for patients requiring advanced treatment options. In December 2025, Orca Biosystems Inc. plans to launch new therapies and is expanding its production facilities with the assistance of USD 100 mn in venture debt funding received from new investor Silicon Valley Bank. The funding will also support ongoing clinical studies for these new therapies.

The company aims to further penetrate North American and European markets, positioning itself for growth in these regions.